Vaccines on demand, part II: future reality.

Area of Science:

• Vaccinology
• Molecular Biology
• Biotechnology

Background:

• Messenger RNA (mRNA) vaccine technology has been extensively studied for rapid pandemic response.
• The SARS-CoV-2 pandemic accelerated the large-scale deployment and evaluation of mRNA vaccine platforms.
• Three main RNA platforms were assessed: conventional mRNA, base-modified mRNA (bmRNA), and self-amplifying RNA (saRNA).

Approach:

• This review synthesizes the current status of mRNA vaccine technologies.
• It evaluates the strengths and limitations of each RNA platform.
• The review discusses the potential advantages of saRNA, contingent on overcoming stability and manufacturing challenges.

Key Points:

• Base-modified mRNA (bmRNA) technology exhibited superior clinical efficacy in trials.
• The success of SARS-CoV-2 mRNA vaccines highlights the platform's potential.
• Challenges remain in mRNA engineering, delivery systems, antigen design, and manufacturing for broader applications.

Conclusions:

• bmRNA technology has proven effective, as evidenced by SARS-CoV-2 vaccine success.
• saRNA technology presents significant advantages if manufacturing and stability issues are resolved.
• Continued innovation is crucial to unlock the full potential of mRNA vaccine technology for diverse disease targets.